These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34445078)

  • 1. A New Smoothened Antagonist Bearing the Purine Scaffold Shows Antitumour Activity In Vitro and In Vivo.
    Zárate AM; Espinosa-Bustos C; Guerrero S; Fierro A; Oyarzún-Ampuero F; Quest AFG; Di Marcotullio L; Loricchio E; Caimano M; Calcaterra A; González-Quiroz M; Aguirre A; Meléndez J; Salas CO
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Smoothened ligands based on the purine scaffold as potential agents for treating pancreatic cancer.
    Espinosa-Bustos C; Bertrand J; Villegas-Menares A; Guerrero S; Di Marcotullio L; Navacci S; Schulte G; Kozielewicz P; Bloch N; Villela V; Paulino M; Kogan MJ; Cantero J; Salas CO
    Bioorg Chem; 2024 Oct; 151():107681. PubMed ID: 39106711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
    Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
    Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
    Li QR; Zhao H; Zhang XS; Lang H; Yu K
    Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype.
    Infante P; Alfonsi R; Ingallina C; Quaglio D; Ghirga F; D'Acquarica I; Bernardi F; Di Magno L; Canettieri G; Screpanti I; Gulino A; Botta B; Mori M; Di Marcotullio L
    Cell Death Dis; 2016 Sep; 7(9):e2376. PubMed ID: 27899820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures.
    Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO
    Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
    Benvenuto M; Masuelli L; De Smaele E; Fantini M; Mattera R; Cucchi D; Bonanno E; Di Stefano E; Frajese GV; Orlandi A; Screpanti I; Gulino A; Modesti A; Bei R
    Oncotarget; 2016 Feb; 7(8):9250-70. PubMed ID: 26843616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABT-199 inhibits Hedgehog pathway by acting as a competitive inhibitor of oxysterol, rather as a BH3 mimetic.
    Wang J; Zhang Y; Huang WJ; Yang J; Tang WG; Huang TM; Tan WF
    Acta Pharmacol Sin; 2021 Jun; 42(6):1005-1013. PubMed ID: 32855528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
    Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
    Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
    Zhang H; Sun Z; Liu Z; Song C
    Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs.
    Kaboli PJ; Bazrafkan M; Ismail P; Ling KH
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):384-400. PubMed ID: 28969581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
    Berardozzi S; Bernardi F; Infante P; Ingallina C; Toscano S; De Paolis E; Alfonsi R; Caimano M; Botta B; Mori M; Di Marcotullio L; Ghirga F
    Eur J Med Chem; 2018 Aug; 156():554-562. PubMed ID: 30025349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A sterol analog inhibits hedgehog pathway by blocking cholesterylation of smoothened.
    Liu YB; He LM; Sun M; Luo WJ; Lin ZC; Qiu ZP; Zhang YL; Hu A; Luo J; Qiu WW; Song BL
    Cell Chem Biol; 2024 Jul; 31(7):1264-1276.e7. PubMed ID: 38442710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B13, a well-tolerated inhibitor of hedgehog pathway, exhibited potent anti-tumor effects against colorectal carcinoma in vitro and in vivo.
    Wu H; Zhang L; Chen B; Ou B; Xu J; Tian N; Yang D; Ai Y; Chen Q; Quan D; Zhang T; Lv L; Tian Y; Zhang J; Wu S
    Bioorg Chem; 2023 Jun; 135():106488. PubMed ID: 36989734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
    Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Smoothened in Cancer.
    Jeng KS; Sheen IS; Leu CM; Tseng PH; Chang CF
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scaffold hopping approach to a new series of smoothened antagonists.
    Lu W; Geng D; Sun Z; Yang Z; Ma H; Zheng J; Zhang X
    Bioorg Med Chem Lett; 2014 May; 24(10):2300-4. PubMed ID: 24726807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.
    Galimberti F; Busch AM; Chinyengetere F; Ma T; Sekula D; Memoli VA; Dragnev KH; Liu F; Johnson KC; Guo Y; Freemantle SJ; Andrew AS; Greninger P; Robbins DJ; Settleman J; Benes C; Dmitrovsky E
    Int J Oncol; 2012 Nov; 41(5):1751-61. PubMed ID: 22923130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo.
    Guo J; Gao J; Li Z; Gong Y; Man X; Jin J; Wu H
    Cancer Lett; 2013 Oct; 339(2):185-94. PubMed ID: 23791879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.